Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.13 +4.0%	$3.57	$1.24 ▼ $4.08	$829.90M	0.96	4.16 million shs	3.10 million shs
KYMR Kymera Therapeutics	$41.75 -1.2%	$43.94	$19.44 ▼ $53.27	$2.99B	2.18	737,635 shs	578,976 shs
SRRK Scholar Rock	$33.28 -3.5%	$35.75	$6.76 ▼ $46.98	$3.20B	0.48	1.27 million shs	785,320 shs
XENE Xenon Pharmaceuticals	$38.60 -0.7%	$33.56	$26.74 ▼ $46.00	$2.98B	1.16	887,321 shs	399,614 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.59%	-3.53%	-16.16%	0.00%	+98.03%
KYMR Kymera Therapeutics	-3.67%	-0.21%	-4.39%	+39.70%	-13.65%
SRRK Scholar Rock	+2.04%	+0.20%	-7.06%	+15.52%	+280.46%
XENE Xenon Pharmaceuticals	+0.57%	+3.27%	+25.51%	+33.85%	-5.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.8098 of 5 stars	3.5	2.0	4.0	2.1	0.8	0.6
KYMR Kymera Therapeutics	3.0873 of 5 stars	4.6	1.0	0.0	3.1	2.5	0.0
SRRK Scholar Rock	4.5598 of 5 stars	4.6	0.0	4.4	2.9	3.3	0.6
XENE Xenon Pharmaceuticals	2.2809 of 5 stars	3.5	1.0	0.0	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.75	115.65% Upside
KYMR Kymera Therapeutics	3.11	Buy	$58.76	40.75% Upside
SRRK Scholar Rock	3.20	Buy	$45.75	37.47% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	37.82% Upside

Current Analyst Ratings Breakdown

Latest AKBA, SRRK, KYMR, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/13/2025	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$203.73M	4.07	N/A	N/A	$0.11 per share	28.45
KYMR Kymera Therapeutics	$47.07M	63.42	N/A	N/A	$13.59 per share	3.07
SRRK Scholar Rock	$33.19M	96.39	N/A	N/A	$2.43 per share	13.70
XENE Xenon Pharmaceuticals	$7.50M	396.84	N/A	N/A	$8.22 per share	4.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	11/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	11/11/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	11/11/2025 (Estimated)

Latest AKBA, SRRK, KYMR, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
KYMR Kymera Therapeutics	N/A	8.32	8.32
SRRK Scholar Rock	0.21	6.33	6.33
XENE Xenon Pharmaceuticals	N/A	15.14	15.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
KYMR Kymera Therapeutics	N/A
SRRK Scholar Rock	91.08%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
KYMR Kymera Therapeutics	16.01%
SRRK Scholar Rock	13.30%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.15 million	257.19 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.97 million	Optionable

AKBA, SRRK, KYMR, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Affinity Asset Advisors LLC

August 28 at 9:02 AM | marketbeat.com

Russell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENE

August 27 at 3:39 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

EntryPoint Capital LLC Makes New $298,000 Investment in Xenon Pharmaceuticals Inc. $XENE

August 25 at 5:07 AM | marketbeat.com

Did Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?

August 24, 2025 | finance.yahoo.com

Wellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 24, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLC

August 23, 2025 | marketbeat.com

Candriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLC

August 22, 2025 | marketbeat.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued

August 21, 2025 | finance.yahoo.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

August 21, 2025 | marketbeat.com

Lord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 19, 2025 | marketbeat.com

What is Chardan Capital's Forecast for XENE FY2025 Earnings?

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for XENE Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for XENE

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst

August 16, 2025 | marketbeat.com

William Blair Has Negative Estimate for XENE Q3 Earnings

August 16, 2025 | marketbeat.com

What is William Blair's Estimate for XENE FY2027 Earnings?

August 15, 2025 | marketbeat.com

Xenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Chardan Capital

August 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, SRRK, KYMR, and XENE Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.13 +0.12 (+3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.12 -0.01 (-0.32%)

As of 04:56 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$41.75 -0.51 (-1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$42.50 +0.75 (+1.80%)

As of 05:37 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Scholar Rock NASDAQ:SRRK

$33.28 -1.19 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$33.78 +0.50 (+1.51%)

As of 05:30 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$38.60 -0.27 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$38.62 +0.02 (+0.04%)

As of 04:33 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time